FDA approves Hibsago, first antisense injectable against chronic hepatitis B
The FDA approves Hibsago, the first antisense injectable against chronic hepatitis B: 19% achieved functional cure in trials. What it means for Mexico.
The US Food and Drug Administration (FDA) approved Hibsago (bepirovirsen) on October 20, 2026, the first antisense oligonucleotide authorized to treat chronic hepatitis B. In phase III trials, 19% of treated patients kept surface antigen undetectable 24 weeks after stopping all treatment, versus 0% in the placebo group.
The drug, developed by the British company GSK, was approved in Japan in August 2026 and reached the United States days before its October 26 target date. Results from the B-Well 1 and B-Well 2 trials were published in The New England Journal of Medicine in May 2026, according to Saludiario. The gap with the current standard is wide: with conventional therapy around 1% of patients reach that outcome, according to Pharmaceutical Technology. For Mexico the figure lands in a context of active surveillance: the Ministry of Health reported 534 hepatitis B cases as of July 19, 2025, 5.33% more than the 507 in the same period of 2024, according to the Epidemiological Bulletin for week 29 cited by UnoTV.
The indication is narrow. Hibsago was authorized for adults without cirrhosis who have been on an antiviral for at least six months, have suppressed viral load and an HBsAg of 3000 IU/ml or less, measured with the test the FDA validated as a complementary diagnostic. The regimen is weekly subcutaneous injections for up to 24 weeks, with the possibility of self-administration after the first dose, and the patient stays on their antiviral for at least 24 more weeks. Among those who started with an HBsAg below 1000 IU/ml, functional cure reached 26%. The label includes two boxed warnings, for serious liver reactions and low platelets, which require periodic blood tests. Tony Wood, GSK's chief scientific officer, noted that this is the first time patients in the United States have the potential to achieve functional cure with a six-month treatment.
GSK projects peak sales of more than 2000 million pounds and expects to have the product available in the United States before the end of 2026, with no announced price. For a healthcare operator in Mexico, three questions remain open: whether COFEPRIS will open its own file, at what price it would arrive and whether the companion test will be available in local laboratories. The Mexican registry has not yet published anything on Hibsago.
This article was written with the assistance of artificial intelligence from verified sources and reviewed by a human editor before publication.